Form 4: Apyx Medical Corp Executive Granted Stock Options

Sentiment:

SEC Form 4


Moshe Citronowicz, Sr. V.P. of Operations at Apyx Medical Corp, was granted stock options to purchase 36,000 shares of common stock.

Summary

  • On May 15, 2025, Moshe Citronowicz, Sr. V.P. of Operations at Apyx Medical Corp, was granted stock options to purchase 36,000 shares of common stock at an exercise price of $1.48.
  • The options vest ratably over 36 months and will be fully vested and exercisable on May 15, 2028.
  • Following the transaction, Mr. Citronowicz directly owns options for 36,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

  • The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

Stock option grants are a common form of executive compensation in the medical device industry, used to attract and retain talent and align their interests with those of shareholders.

Stakeholder Impact

  • Shareholders may view the stock option grant as a positive incentive for the executive team.
  • Employees may see this as a sign of confidence in the company's future.

Key Dates

DateDescription
05/15/2025Date of earliest transaction and grant date of stock options.
05/15/2028Date the stock options become fully vested and exercisable.
05/15/2035Expiration date of the stock options.
05/19/2025Date of Form 4 signature.

Keywords

stock options, Form 4, executive compensation, beneficial ownership, Apyx Medical Corp, Citronowicz, APYX

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.